Share Email Print
cover

Proceedings Paper

Photodynamic therapy platform for glioblastoma and intrabronchial tumors
Author(s): Lasse Orsila; Jukka-Pekka Alanko; Visa Kaivosoja; Toomas Uibu
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Photodynamic therapy (PDT) is bringing new, effective, and less invasive, possibilities for cancer treatment. ML7710 (Modulight Inc.) medical laser system offers a platform for performing PDT for multiple indications and drugs. Latest avenue is glioblastoma treatment with 5-Aminolevulinic acid (ALA-5) and 635-nm light, where clinical trials are about to begin. Preliminary work suggests major advantages in treatment control, including active in-situ feedback. ML7710 platform has already proven itself for clinical work with intrabronchial obstructive tumors. Preliminary result with 10 patients show that intrabronchial tumors, that strongly affect both the survival and the performance of the patient, can be significantly reduced with ML7710 operated at 665 nm and sodium chlorine E6 photosensitizer. The aim in most of the patients has been a palliative recanalization of the bronchial lumen in order to alleviate the symptoms such as breathlessness and hemoptysis. The illumination dose for the target area was 50–75 J/cm2. All the patients have received multimodality cancer treatment using other intrabronchial interventions, radiotherapy and chemotherapy as needed. In most of the patients, satisfactory treatment results were achieved and it was possible to restart chemotherapy in several patients. In one patient with local cancer a complete remission was established. PDT has also the advantage that it is possible to give PDT after a maximum dose of radiation therapy has already been used and fewer side effects if used in locally advanced intraluminar lung cancer.

Paper Details

Date Published: 8 February 2018
PDF: 7 pages
Proc. SPIE 10480, Clinical and Translational Neurophotonics 2018, 1048007 (8 February 2018); doi: 10.1117/12.2297229
Show Author Affiliations
Lasse Orsila, Modulight, Inc. (Finland)
Jukka-Pekka Alanko, Modulight, Inc. (Finland)
Visa Kaivosoja, Modulight, Inc. (Finland)
Toomas Uibu, Tampere Univ. Hospital (Finland)


Published in SPIE Proceedings Vol. 10480:
Clinical and Translational Neurophotonics 2018
Steen J. Madsen; Victor X. D. Yang, Editor(s)

© SPIE. Terms of Use
Back to Top